{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:22:03Z","timestamp":1771935723595,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed\/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient\u2019s documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton\u2019s tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient\u2019s CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.<\/jats:p>","DOI":"10.3389\/fonc.2026.1724213","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:15Z","timestamp":1771305495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuejiao","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical School of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefen","family":"You","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenghua","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24934","article-title":"Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States 1973-2005","volume":"126","author":"Mbulaiteye","year":"2010","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105703","DOI":"10.1016\/j.humpath.2024.105703","article-title":"Burkitt lymphoma","volume":"156","author":"Fang","year":"2025","journal-title":"Hum Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt lymphoma","volume":"8","author":"Lopez","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244212","article-title":"The functional interaction between epstein-barr virus and MYC in the pathogenesis of burkitt lymphoma","volume":"16","author":"Solares","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of hematolymphoid tumors: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt lymphoma international prognostic index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00351-X","article-title":"Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet","volume":"12","author":"Ribrag","year":"2025","journal-title":"Lancet Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.270876","article-title":"Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study","volume":"106","author":"Zayac","year":"2021","journal-title":"Hematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028549","article-title":"Burkitt lymphoma: click here to add to CAR-T","volume":"145","author":"Hawkes","year":"2025","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab\u00a0plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomized, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41571-024-00975-y","article-title":"Benefit with glofitamab plus chemotherapy in transplant-ineligible\u00a0R\/R DLBCL","volume":"22","author":"Romero","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029117","article-title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","volume":"146","author":"Brooks","year":"2025","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","article-title":"Evidence-based expert consensus on the management of primary central nervous system lymphoma in China","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: A 13-case series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1724213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:28:46Z","timestamp":1771932526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1724213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1724213"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1724213","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1724213"}}